Elevation Oncology Management
Management criteria checks 0/4
Elevation Oncology's CEO is Joe Ferra, appointed in Jan 2023, has a tenure of 1.83 years. total yearly compensation is $1.24M, comprised of 47.5% salary and 52.5% bonuses, including company stock and options. directly owns 0.17% of the company’s shares, worth $61.77K. The average tenure of the management team and the board of directors is 1.8 years and 2.4 years respectively.
Key information
Joe Ferra
Chief executive officer
US$1.2m
Total compensation
| CEO salary percentage | 47.5% |
| CEO tenure | 1.8yrs |
| CEO ownership | 0.2% |
| Management average tenure | 1.8yrs |
| Board average tenure | 2.4yrs |
Recent management updates
Recent updates
Elevation Oncology: Mid-2024 EO-3021 Data Could Get Ball Rolling
May 03Elevation Oncology: Rising On News, But Not The Time To Buy
Jan 17Elevation Oncology GAAP EPS of -$0.86 misses by $0.07
Aug 04Elevation Oncology secured $50M loan facility with K2 HealthVentures
Jul 28We're Hopeful That Elevation Oncology (NASDAQ:ELEV) Will Use Its Cash Wisely
May 10
We're Not Very Worried About Elevation Oncology's (NASDAQ:ELEV) Cash Burn Rate
Jan 25Companies Like Elevation Oncology (NASDAQ:ELEV) Are In A Position To Invest In Growth
Sep 25CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$42m |
| Jun 30 2024 | n/a | n/a | -US$40m |
| Mar 31 2024 | n/a | n/a | -US$39m |
| Dec 31 2023 | US$1m | US$590k | -US$46m |
| Sep 30 2023 | n/a | n/a | -US$57m |
| Jun 30 2023 | n/a | n/a | -US$85m |
| Mar 31 2023 | n/a | n/a | -US$95m |
| Dec 31 2022 | US$775k | US$446k | -US$95m |
| Sep 30 2022 | n/a | n/a | -US$86m |
| Jun 30 2022 | n/a | n/a | -US$59m |
| Mar 31 2022 | n/a | n/a | -US$44m |
| Dec 31 2021 | US$6m | US$238k | -US$32m |
Compensation vs Market: Joe's total compensation ($USD1.24M) is above average for companies of similar size in the US market ($USD647.72K).
Compensation vs Earnings: Joe's compensation has increased whilst the company is unprofitable.
CEO
Joe Ferra (49 yo)
1.8yrs
Tenure
US$1,243,856
Compensation
Mr. Joseph J. Ferra, Jr., also known as Joe, served as a Chief Financial Officer at Elevation Oncology, Inc. since June 2021 until July 12, 2023 and served as its Interim Chief Executive Officer until July...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 1.8yrs | US$1.24m | 0.17% $ 61.8k | |
| Chief Scientific Officer | 2.7yrs | US$771.04k | 0% $ 0 | |
| Chief Medical Officer | 3.1yrs | US$836.06k | 0% $ 0 | |
| CFO & Secretary | 1.3yrs | no data | 0.0024% $ 859.5 | |
| Head of Tech Ops | 1.4yrs | no data | no data | |
| Senior Director of Corporate Communications & Investor Relations | no data | no data | no data | |
| Senior VP & General Counsel | 2.8yrs | no data | no data | |
| Senior Vice President of Business & Corporate Development | less than a year | no data | no data |
1.8yrs
Average Tenure
47.5yo
Average Age
Experienced Management: ELEV's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 1.3yrs | US$1.24m | 0.17% $ 61.8k | |
| Independent Director | 3.5yrs | US$86.48k | 0% $ 0 | |
| Independent Chairman of the Board | 5.5yrs | US$113.08k | 0% $ 0 | |
| Independent Director | 4.5yrs | US$84.48k | 0.080% $ 28.8k | |
| Chairman of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | less than a year | no data | 0% $ 0 | |
| Independent Director | less than a year | no data | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
2.4yrs
Average Tenure
61yo
Average Age
Experienced Board: ELEV's board of directors are not considered experienced ( 2.4 years average tenure), which suggests a new board.